Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC7UF3
|
|||
| Drug Name |
Remlarsen
|
|||
| Indication | Keloid [ICD-11: EE60; ICD-10: L73.0] | Phase 2 | [1] | |
| Company |
miRagen Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | microRNA hsa-miR-29b (MIR29b) | Target Info | Replacement | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03601052) Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids. U.S. National Institutes of Health. | |||
| REF 2 | A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol. 2019 May;139(5):1073-1081. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.